Page 135 - Haematologica June

MYD88L265P mutation detection by ddPCR on BM, PB and ctDNA
correlation with MYD88 L265P somatic mutation status, clinical features, and out- come. Biomed Res Int. 2014;2014:809103.
33. Kang Q, Henry NL, Paoletti C, et al. Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. Clin Biochem. 2016;49(18):1354–1360.
34. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell-free DNA: Preanalytical considerations. Clin Chim Acta. 2013;424: 222–230.
35. Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406(26):6499–6512.
36. Gustine J, Meid K, Xu L, Hunter ZR, Castillo JJ, Treon SP. To select or not to select? The role of B-cell selection in deter- mining the MYD88 mutation status in Waldenström macroglobulinaemia. Br J Haematol. 2017;176(5):822–824.
37. Xu L, Hunter ZR, Yang G, et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined signifi- cance. Leukemia. 2014;28(8):1698–1704.
38. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexametha- sone (CaRD) treatment offers a neuropa- thy-sparing approach for treating
Waldenström's macroglobulinemia. Blood.
2014;124(4):503-510.
39. Paiva B, Montes MC, García-Sanz R, et al.
Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differ- ential diagnosis and risk stratification. Leukemia. 2014;28(1):166–173.
40. Kotrova M, van der Velden VHJ, van Dongen JJM, et al. Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL. Bone Marrow Transplant. 2017;52(7):962–968.
41. Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B- cell lymphoma by immunoglobulin high- throughput sequencing. Blood. 2015;125 (24):3679–3687.
42. Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT mon- itoring in patients with untreated diffuse large B-cell lymphoma: a correlative bio- marker study. Lancet Oncol. 2015;16(5): 541–549.
43. Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14): 1947–1957.
44. Rustad EH, Coward E, Skytøen ER, et al. Monitoring multiple myeloma by quantifi- cation of recurrent mutations in serum. Haematologica. 2017;102(7):1266–1272.
45. Sarkozy C, Huet S, Carlton VEH, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma cir- culating clonal IG-VDJ sequences at diag- nosis in patients with follicular lymphoma. Oncotarget. 2017;8(5):8765–8774.
46. Bruscaggin A, Spina V, Di Trani M, et al. Genotyping of classical Hodgkin lym- phoma on the liquid biopsy. Hematol Oncol. 2017;3564–3565.
47. Camus V, Sarafan-Vasseur N, Bohers E, et al. Digital PCR for quantification of recur- rent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lym- phoma. Leuk Lymphoma. 2016;57(9): 2171–2179.
48. Alcaide M, Yu S, Bushell K, et al. Multiplex doplet digital PCR quantification of recur- rent somatic mutations in diffuse large B- cell and follicular lymphoma. Clin Chem. 2016;62(9):1238–1247.
49. Hattori K, Sakata-Yanagimoto M, Suehara Y, et al. Clinical significance of disease-spe- cific MYD88 mutations in circulating DNA in primary central nervous system lym- phoma. Cancer Sci. 2018;109(1):225–230.
50. Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, et al. The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol. 6 Dec 2017. [Epub ahead of print].
haematologica | 2018; 103(6)
1037